Clinical Trial News Archive
Get news By email or subscribe to our News feeds.
October 2011
October 3
EntreMed's ENMD-2076 Demonstrates Promising Activity in a Phase 2 Study in Platinum-Resistant Ovarian Cancer Patients
Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin
In Reversing Motor Nerve Damage, Time Is of the Essence
Biovest to Present on Regulatory Strategy for BiovaxID Cancer Vaccine at MD Becker Cancer Immunotherapy Conference
Kineta Scientists to Present Novel Antiviral Research Findings at International Conference
Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference
October 4
October 5
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to Allopurinol Alone
Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer
Sunshine Biopharma's anti-cancer compound, Adva-27a, found to be a strong Topoisomerase II inhibitor
Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer
New FDA Study Finds No Developmental Effects from BPA
October 6
October 7
Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial in Healthy Adults Over Age 40
Phase I/II Study Evaluating Abraxane Clinical Potential in Patients With Advanced Pancreatic Cancer Published in the Journal of Clinical Oncology Online
Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit
New Oral Drug Found to Reduce Relapses in Multiple Sclerosis atients
October 10
October 11
October 12
New Study Shows Cialis Significantly Improved Study Endpoints in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia
Dynavax Reports Positive Immunogenicity Data From an Analysis of Hypo-Responsive Populations in HEPLISAV Phase 3 Trial
CytRx's ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting
October 13
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis
POZEN Reports Top-Line Data from Long-Term Safety Study of PA32540
Merck's ISENTRESS (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
Phase 1/2 Clinical Trial Results of Perifosine Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
The US Oncology Network-Milliman Study Shows That Evidence-Based Guidelines Could Reduce Costs in Colon Cancer Patients Receiving Chemotherapy by More Than $50,000 While Maintaining Quality Outcomes
Scripps Research Scientists Reveal Surprising Picture of How Powerful Antibody Neutralizes HIV
Survey of Nurse Practitioners Finds Oral Estrogen Therapy Is Prescribed More Often Than Transdermal And Examines External Influences That Affect Prescribing Practices
KGI Professor Links MicroRNA Gene to Aggressive Skin Cancer
October 14
October 16
Hepatitis C Phase 2A Trial Positive Results
Daval International Announces Positive Phase II Results for AIMSPRO(R) as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
Furiex Pharmaceuticals Announces Scientific Publications for JNJ-Q2
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review in Phase III Program
October 17
Novartis Drug Gilenya (fingolimod) has more than 20,000 Patient-years of Exposure and Shows up to 71% Reduction in Annualized Relapse Rates in MS Patients with Highly Active Disease
Multi-center Clinical Trial Shows ParaPRO's Spinosad Eradicates Head Lice and Nits
Genetic Profile Identified for Alzheimer's Patients Showing Heightened Response to Accera's Breakthrough Product Axona(R)
Theracrine Announces Publication Identifying Potential Novel Cancer Spread Target
October 18
The Medicines Company's MDCO-2010 Meets Clinical Trial Objectives in Patients Undergoing Open-Heart Surgery
Roche Reports Positive Study of Herceptin Given By Subcutaneous Injection
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Pacira Pharmaceuticals, Inc. Announces EXPAREL Data to Be Presented at Upcoming Medical Meetings
Pevion's Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
October 19
Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
Data about Early Use and Long-Term Benefit of Tysabri Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS
Canadian Journal of Cardiology Publishes Report on Delayed vs. Immediate Coronary Stenting
Genfit: A Hospital-Based Clinical Study Demonstrates the Action of Gft505 on the Liver
New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19
Anadys Announces Positive 12-Week Data for Setrobuvir in Phase 2b Hepatitis C Study
October 20
Cubist to Feature Antibiotic Development Programs at 49th IDSA
Galderma Announces Positive Phase 2b Results for Investigational Compound Targeting Redness of Rosacea
Isentress Shown to Be More Effective in Ongoing Head-to-Head HIV Study
Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial
DIFICID Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Interim Phase IIb Data for Merck's VICTRELIS (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting
Treatment with COPAXONE in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Setting
Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
Galderma Announces Positive US Pivotal Interim 6-Month Results for EMERVEL Classic Lidocaine Compared to Juvederm Ultra
African American Women With Gestational Diabetes Face High Long-term Diabetes Risk
ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day
Tryton's Innovative Solution Highlighted at Annual European Bifurcation Club Meeting
October 21
Boceprevir based therapy cleared the hepatitis C virus in 70 percent of patients coinfected with hepatitis C and HIV-1
Additional Data From Pfizer's Prevnar 13 Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes
EU Study Shows Once-Daily Lisdexamfetamine Dimesylate (LDX) Effective for Symptom Control in Children and Adolescents With ADHD
October 24
NanoViricides' Anti-Virus Technology Published in Bionanotechnology II: Global Prospects
NPS Pharmaceuticals Reports Upcoming Presentations at American College of Gastroenterology Annual Scientific Meeting
Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK Combination Therapy
Novartis Phase II Data Show AIN457 Provided Rapid and Significant Relief of Symptoms in up to 81% of Patients with Psoriasis
New Frontier in the Treatment of Type 1 Diabetes -- Italian Researchers Present Findings in the Improvement of the Efficacy of Pancreatic Islet Transplantation
Study Hints at Possible Therapeutic Strategy to Combat Premature Birth
October 25
October 26
Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
Butrans (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
October 27
New England Journal of Medicine Publishes Additional Efficacy and Safety Data for Gardasil in Males
Linaclotide provides long term relief from the symptoms of irritable bowel syndrome with constipation
Full Phase III data highlight the efficacy and tolerability of Sativex as therapy for the treatment of spasticity in MS
Interim Results Presented from Long-Term, Open-Label Extension Study Evaluating Lundbeck's ONFI (clobazam) in the Adjunctive Treatment of Drop Seizures Associated with LGS
Favorable Clinical Trial Results for Ampion in Treatment of Osteoarthritis (AIK) Allows Testing as a Monotherapy Against "Standard of Care," Ahead of Schedule
Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
Chinese Study Finds No Association between BPA and Diabetes in Large Scale Clinical Trial
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Synergy Pharmaceuticals Presentations at 2011 American College of Gastroenterology Annual Scientific Meeting
ULURU Inc. Announces Additional Data Supporting Altrazeal(R) Use in Diabetic Foot Ulcers
Ironwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation
October 28
UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting
CBIO Lupus Data Published By Oxford Journals
Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
VTT Identified Specific Bacteria Which Precede Autoimmune Diabetes
Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis
October 31
YM BioSciences Nimotuzumab Results Reported at SIOP Conference
Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
Teva Presents New Data on Qnsal at the 2011 American College of Allergy, Asthma and Immunology Annual Meeting
New Data on Cimzia (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
InflammaGen Therapeutics to Present Case Review of InflammaGen Shok-Pak at BIO-Europe 2011
Furiex Pharmaceuticals Study Results to be Presented at the American College of Gastroenterology 2011 Annual Scientific Meeting
NPS Pharmaceuticals to Host Conference Call to Discuss Data Reported at American College of Gastroenterology Annual Scientific Meeting
New Data on Cimzia (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn?s disease
Phase 3 Gattex (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome
